AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Orlistat produced significant weight loss, improved blood sugar control, and reduced cardiovascular risk factors in overweight, insulin-treated patients with type 2 diabetes, Dr. George Bray reported at the annual scientific sessions of the American Diabetes Association.
Roche, which manufactures orlistat under the name Xenical, is petitioning the FDA to use the drug as adjunctive treatment in overweight or obese type 2 diabetic patients.
In a Roche-sponsored study 269 obese insulin-treated type 2 diabetic patients were randomized to receive 120 mg orlistat three times daily plus diet, while 266 took a placebo and followed the diet. After 52 weeks, the ...
Source: HighBeam Research, Orlistat in Type 2 Diabetes. (Diabetes).